Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupivacaine + sufentanil is a fixed-dose combination of two drugs used primarily for regional anesthesia and analgesia, especially in obstetric settings such as labor and cesarean delivery. Bupivacaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting nerve impulse conduction and producing loss of sensation. Sufentanil is a potent synthetic opioid agonist at the mu-opioid receptor, providing strong analgesic effects. When combined (typically via epidural or intrathecal administration), this regimen offers superior pain relief compared to bupivacaine alone—prolonging the duration of analgesia, reducing breakthrough pain during surgery or labor, shortening sensory block onset time, and delaying the need for additional analgesics. The addition of sufentanil may increase certain side effects such as pruritus but does not significantly increase adverse maternal or fetal outcomes when used appropriately[1][2][3][4][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + sufentanil.